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Objectives: Tumor-associated antigens (TAAs) are frequently overexpressed in several cancer types. The
aim of this study was to investigate the expression of TAAs in breast cancer.
Material and methods: A total of 250 selected invasive breast cancers including 50 estrogen receptor
(ER)-positive (Luminal B like), 50 triple-negative (TN), 50 ER-positive lobular type, 50 ER- and proges-
terone receptor (PgR)-positive (Luminal A like) and 50 cerbB2-positive breast cancers, were assessed for
New York esophageal squamous cell carcinoma-1 (NY-ESO-1), Wilms tumor antigen (WT-1) and PRef-
erentially expressed Antigen of MElanoma (PRAME) antigen expression by immunohistochemistry (IHC).
Results: A signiﬁcantly higher expression of cancer testis (CT)-antigens NY-ESO-1 and WT-1 antigen was
detected in TN breast cancers compared with ER-positive tumors. NY-ESO-1 overexpression (score
2 þ and 3þ) assessed by monoclonal and polyclonal antibodies was detected in 9 (18%) TN cancers as
compared to 2 (4%) ER-positive tumors (p ¼ 0.002). WT1 over-expression (score 2 þ and 3þ) was
conﬁrmed in 27 (54%) TN tumor samples as compared to 6 (12%) ER-positive (p < 0.0001). PRAME over-
expression (score 2 þ and 3þ) was detected in 8 (16%) HER2 positive tumor samples as compared to no
TN and ER-positive cancers (p ¼ 0.0021).
Conclusions: NY-ESO-1 and WT1 antigens are overexpressed in TN breast cancers. Because of the limited
therapeutic options for this patient subgroup, CT antigen-based vaccines might prove to be useful for
patients with this phenotype of breast cancer.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Research on tumor-associated antigen (TAA) peptides has
identiﬁed a large collection of peptide epitopes that have been and
are being used for the vaccination of cancer patients [1]. The use of
peptide-based vaccines offers several potential advantages, such as
the simplicity of peptide administration in the clinical setting, the
possibility of treating only those patients whose tumorsDevelopment for Innovative
S, Via Ripamonti 435, 20141,
igliano).
Ltd. This is an open access article uoverexpress the antigens, and the availability of in vitro or ex vivo
assays that can assess patients’ immune response to vaccine
epitopes.
Over the last twenty years, the implementation of novel meth-
odologies such as next generation sequencing and bioinformatics
tools led to the identiﬁcation of several TAAs. Among all recognized
TAAs, a great interest has been focused on cancer testis (CT) and
differentiation antigens, which are frequently downregulated in
somatic adult tissues, while become aberrantly re-expressed in
various malignancies [2e4]. These features render these antigens
as appealing targets to generate anti-cancer vaccines and other
types of immunotherapy. Moreover, several works suggest the as-
sociation between TAAs expression and poorer outcomes across a
broad spectrum of solid tumors, as well as a higher prevalence innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1









N % N % N % N % N %
All samples 50 100 50 100 50 100 50 100 50 100
Histotype
Ductal 49 98 42 84 0 0 39 78 35 70
Lobular 0 0 0 0 50 100 0 0 0 0
Others 1 2 8 16 0 0 11 22 15 30
Grade
1 8 16 5 10 10 20 1 2 1 2
2 24 48 18 36 40 80 16 32 6 12
3 17 34 26 52 0 0 30 60 42 84
Unknown 1 2 1 2 0 0 3 6 1 2
pT
1 40 80 32 64 39 78 31 62 32 64
2 10 20 14 28 11 22 15 30 17 34
3-4 0 0 4 8 0 0 4 8 1 2
pN
0 25 50 31 62 33 66 25 50 34 68
1 16 32 8 16 5 10 14 28 8 16
2-3 8 16 8 16 3 6 7 14 7 14
x 1 2 3 6 9 18 4 8 1 2
ER
0 0 0 18 36 1 2 10 20 50 100
1-49 0 0 7 14 3 6 10 20 0 0
50 50 100 25 50 46 92 30 60 0 0
PgR
0 0 0 21 42 16 32 30 60 50 100
1-49 0 0 19 38 12 24 14 28 0 0
50 50 100 10 20 22 44 6 12 0 0
Ki-67
<20% 28 56 12 24 42 84 9 18 5 10
20% 22 44 38 76 8 16 41 82 45 90
Fig. 1. Example of assessing H-score in a case of breast cancer tested for NY-ESO-1.
In this picture, about half of the neoplastic cells is stained with the brown chromogen
and the remaining half of the cells is blue (no staining). Cells with strongly stained
nuclei (3 þ positivity) are circumscribed by the red line and these cells represent about
95% of all the colored cells in the picture (95% of 50% ¼ 47,5%); the remaining 2,5% of
colored cells are cells with moderately stained nuclei (2 þ positivity), marked with the
red arrows, and cells with weakly stained nuclei (1 þ positivity), marked with black
arrows. The percentage of 2 þ cells is about 2% and the percentage of 1 þ cells are 0,5%.
The H-score is 147, generated adding the percentage of cells for the respective intensity
of staining, as follows: (50  0) þ (0,5  1) þ (2  2) þ (47,5  3) ¼ 147. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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intense research efforts have been directed toward the possible use
of TAAs in the development of therapeutic vaccines due to their
potent immunogenicity [10]. Several clinical trials with vaccines
containing TAAs, such as New York esophageal squamous cell
carcinoma-1 (NY-ESO-1), Wilms tumor antigen (WT-1) and PRef-
erentially expressed Antigen of MElanoma (PRAME), accrued or are
actually accruing patients withmelanoma, lung, ovarian, and breast
cancers [11e20]. However, only few studies have investigated the
expression of these TAAs in breast cancer and, in particular, across
breast cancer subtypes [20e24].
The aim of this study was to assess the immunoreactivity for the
TAAs NY-ESO-1, PRAME and WT-1 in a large series of breast cancer
tumor samples classiﬁed, according to immunophenotype, in triple
negative (TN), Luminal B-like, lobular type, human epidermal
growth factor receptor 2 (HER2)-positive, and estrogen receptor
(ER)- and progesterone receptor (PgR)-positive (Luminal A-like)
human breast cancers.
2. Material and methods
2.1. Study population
Demographic, clinical, and pathological data of consecutive
early breast cancer patients who underwent surgery at the Euro-
pean Institute of Oncology (Milan, Italy) between June 1995 and
July 2002 were collected from the institutional database. Tumor
types were classiﬁed according to the World Health Organization
Histological Classiﬁcation of Breast Tumors, as modiﬁed by Rosen
and Obermann [25]. Tumor grading was assessed according to
Elston and Ellis criteria [23].
A total of 250 cases of invasive breast cancer were selected and
categorized, according to ER, PgR, HER2 status, and Ki67 labelling
index, in: Luminal B like, deﬁned as ER-positive with Ki67 > 14%
(n ¼ 50); Luminal A like, deﬁned as ER- and/or PgR-positive more
than 50% (N ¼ 50); lobular histology (n ¼ 50); HER2-positive,
deﬁned as any ER/PgR status and HER2þ (n ¼ 50); and TN, deﬁned
as the lack of ER, PgR, and HER2 (n ¼ 50).
All cases were examined for NY-ESO-1, PRAME and WT1
expression by immunohistochemistry (IHC).
2.2. Immunohistochemistry
ER, PgR status, Ki-67 labelling index (determined with the MIB1
monoclonal antibody) were assessed as previously reported
[24,25]. HER2 IHC expression was evaluated using a 1/400 dilution
of a polyclonal antiserum (Dako, Glostrup, Denmark). All tumors
with equivocal (IHC 2þ) results were tested for gene ampliﬁcation
by ﬂuorescence in situ hybridization (FISH; Vysis PathVysion;
Abbott, Chicago, IL), according to the international guidelines [26].
We deﬁned as ER-positive tumors those showing ER and PgR
expression in 50% neoplastic cells. Triple negative tumors were
characterized by lack of immunoreactivity for ER and PgR, and by a
negative (by both IHC and FISH) HER2 status. Slides were hybrid-
ized with probes to LSI HER-2/neu and CEP17.
NY-ESO-1 (monoclonal antibody E978 provided by Ludwig
Institute for Cancer Research, at a working dilution of 1:200, and
polyclonal antibody 195 provided by GSK, at a working dilution of
1:4000), WT1 (DakoCytomation, monoclonal antibody 6FeH2, at a
working dilution of 1:200) and PRAME (Abcam, policlonal antibody
ab32185, at a working dilution of 1:1600) expression has been
investigated by IHC on whole tissue sections. Tissue specimens
were dewaxed and heated in an antigen retrieval solution [EDTA
buffer (1 mM, pH 8.0)] at 99 C for 15 min (NY-ESO-1 monoclonal
antibody) or 30 min (NY-ESO-1 polyclonal antibody, WT1 and
G. Curigliano et al. / The Breast 49 (2020) 202e209204PRAME). The sections were then incubated with the antibodies
overnight at 4 C (NY-ESO-1 monoclonal antibody and PRAME) or
for 30min at room temperature (NY-ESO-1 polyclonal antibody and
WT1). The DAKO EnVision Mouse was used as a detection system
and diaminobenzidine tetrahydrochloride as a chromogen. Sec-
tions of normal human testis were used as positive control for NY-
ESO-1 and PRAME reactions; vascular endothelium was used as
positive inner control for WT1.
2.3. Scoring
NY-ESO-1, PRAME, and WT-1 immunohistochemical results
were scored using a semiquantitative scoring system similar to the
previously described immunohistochemical-score [27]. This
method considers both the percentage of immune-reactive cells
and the staining intensity. The percentage of positive cells is then
multiplied by the intensity of staining (1þ, 2þ, or 3þ), and the ﬁnal
score ranges from 0 (no staining) to 300 (diffuse and strong im-
munostaining of all the tumor cells).
2.4. Statistical methods
Antigen expression (presence versus absence) among groups
was evaluated using Fisher’s exact test (two proportions) or a chi-
square test (more than two proportions). Different cut-offs of
expression (i.e. 1þ, 2þ and 3þ) were considered to deﬁne presence
of antigen expression. Kruskal-Wallis test was used for comparison
of expression scores among different groups. P-values less than
0.05 were considered as statistically signiﬁcant. All tests were two-
sided.Fig. 2. Comparison between mouse monoclonal NY-ESO-1 and rabbit policlonal NY-ESO
carcinoma. a,b) Mouse monoclonal NY-ESO-1 positive staining [x 10 (a) e x 40 (b)]. c,d) Ra3. Results
3.1. Pathological characteristics
From June 1995 to July 2002, a total of 4000 pT1-3 pN0-3 M0
early breast cancer patients were included in the institutional
database. Among this patient population, a total of 250 cases of
invasive breast cancer were identiﬁed. Tumor stage was pT1a-c for
174 patients, pT2 for 67 patients 3 and pT3-4 for 9 patients. Nodal
involvement was present in 84 patients, while 166 were staged as
pN0/pNX.
According to the histotype, 200 tumors were classiﬁed as
invasive ductal and 132 displayed a Ki67 labelling index 20%.
Lobular histology was identiﬁed in 50 cases. Baseline pathological
characteristics of all breast tumors are listed in Table 1.
3.2. Expression of NY-ESO-1, WT1 and PRAME in breast cancer
samples
All samples were examined for NY-ESO-1 (mono and polyclonal
antibody), WT1 and PRAME expression by IHC (Figs. from 1 to 4). A
heterogeneous staining pattern was present within speciﬁc tumor
samples, ranging from 1 þ to 3þ. In Fig. 5, the visual scale shows
intensity (red for 3þ, green for 2þ and blue for 1þ) and percentage
of staining for each one of the tumor samples. The expression of all
antigens in the different subpopulations of breast cancer are
summarized in Table 2.
NY-ESO-1 over-expression (score 2þ) by monoclonal anti-
bodies was documented in 9 (18%) TN tumors, but only in 2 (4%) ER-
positive (p ¼ 0.002). Similar results were obtained by means-1 immunohistochemical expression in a case of triple negative inﬁltrating ductal
bbit policlonal NY-ESO-1 positive staining [x 10 (c) e x 40 (d)].
Fig. 3. WT1 immunohistochemical expression. a,b) Nuclear staining in two cases of endocrine-responsive inﬁltrating ductal carcinoma (x 20, anti-WT1). c,d) Citoplasmic staining
in a case of triple-negative inﬁltrating ductal carcinoma (c) and in a medullary carcinoma of moderately endocrine-responsive group (d) (x 20, anti-WT1).
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TN than in ER-positive tumors (18% vs 0%; p ¼ 0.0007).
WT1 expression (score 2þ) was detected in 27 (54%) TN can-
cers, while only in 6 (12%) and 3 (6%) cases of ER-positive and
HER2-positive, respectively (p < 0.0001). Conversely, PRAME was
overexpressed (score 2þ) in 8 (16%) HER2-positive tumor sam-
ples, while it was not expressed in TN and ER-positive tumors
(p ¼ 0.0021).
Overall, no associations were found between pathological fea-
tures of disease and NY-ESO-1, WT1, and PRAME over-expression
(score 2þ) (data not showed).4. Discussion
Our study results showed that TN breast cancers frequently
display a higher expression of WT1 and NY-ESO-1 antigens,
corroborating the results of other studies that demonstrated a
reduced expression of these antigens in ER-positive breast cancers
as compared to TN tumors [18e22,28,29]. Conversely, in our work
we did not ﬁnd signiﬁcant differences in terms of PRAME expres-
sion in TN tumors as compared to other breast cancer subtypes, as
suggested in previous studies [30]. Such discrepancy can be
partially explained by the use of monoclonal antibodies that bind
different epitopes of PRAME and WT1 antigens.
DNA microarray proﬁling have led to the identiﬁcation of
invasive breast cancer subgroups with common molecular features
and to the recognition of breast cancer as a heterogeneous entity
[31e35]. Choice of systemic therapies for breast cancer patients
includes the identiﬁcation of potential targets based on genetic
signature and/or IHC [36]. In this respect, the TN subtype ischaracterized by a higher expression of the proliferation cluster of
genes [31] with an elevated number of potential targets for novel
therapies, included epidermal growth factor receptor (EGFR)
overexpression and upregulation in endothelial growth factors
[37]. However, disappointing results have been obtained by tar-
geting these molecules/pathways in the context of clinical trials
[38]. Interestingly, some authors revealed that human cells lacking
BRCA1, including TN breast cancer cells, may be sensitive to drugs
that cause double-strand breaks in DNA [39] (e.g. alkylating agents)
and, more recently, biological agents such as poly (ADP-ribose)
polymerase inhibitors (PARP-inhibitors) [39e41]. These preclinical
and clinical evidences paved the way for implementing personal-
ized therapies also in the TN subtype.
The identiﬁcation of clinical characteristics and biomarkers
associated with resistance to standard therapies represents a
crucial step in the development of the most effective therapeutic
approaches. Properly selecting patients who most likely beneﬁt
from a given therapy might allow to better understand patient
populations and clinical setting in which investigate new thera-
peutic strategies. Considering breast cancer, the neoadjuvant
studies represent excellent platforms to perform biomarker anal-
ysis studies and to test new drugs in selected patient populations.
Indeed, TN tumors display higher rates of pathological complete
response (pCR) after neoadjuvant chemotherapy compared to the
hormone receptor-positive subset [42]. However, several studies
demonstrated that the 5-year disease-free survival (DFS) of TN
tumors is signiﬁcantly worse than all other breast cancer subtypes
[42,43]. Importantly, patients with ER-positive residual tumors
present with better survival compared to patients with ER-negative
tumors not achieving a pCR [43]. These scant survival outcomes are
Fig. 4. PRAME immunohistochemical expression. a) PRAME positive staining in a lobular carcinoma (x 40, anti-PRAME). b) PRAME positive staining in a carcinoma of moderately
endocrine-responsive group (x 40, anti-PRAME). c,d) PRAME positive staining in two cases of breast carcinoma with HER2 overexpression (x 40, anti-PRAME).
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TN breast cancer patients who do not achieve pCR after neo-
adjuvant chemotherapy. In this setting, only capecitabine mono-
therapy demonstrated activity, according to the CREATE-X trial
results [44], and it is currently the only recommended therapy for
these patients in the clinical practice. In this context, the imple-
mentation of new treatments in the post-neoadjuvant setting is a
topic of a great interest. Our results are of clinical relevance for such
subpopulation of patients, speciﬁcally in the adjuvant and post-
neoadjuvant settings of treatment. In our hypothesis, patients
with TN breast cancer and residual disease after preoperative
chemotherapy represent the ideal setting to test the efﬁcacy of a
vaccination strategy. To date, vaccines for breast cancer have been
mainly investigated in end-stage diseases.
By contrast, ever-growing evidences suggest that immuno-
therapy might be most effective when administered in patients
with early phase tumors and minimal burden of disease, also
considering the smaller number of immune escape mechanisms
adopted by tumor cells in these settings. To date, several clinical
trials testing vaccines against antigens, including MUC1, CEA, and
HER2, have been completed [45]. In addition, other vaccines
including members of the MAGE and ESO families have been tested
in clinical trials for patients with melanoma and lung cancer with
controversial results [46,47]. Despite CT antigens potentially offer
the opportunity for fostering vaccine development and therapy for
a broad spectrum of cancers, other determinants involved in anti-
tumor immune response have to be considered when we
approach to design new trials investigating therapeutic cancer
vaccines. These factors included the presence of an immune-
suppressive tumor microenvironment such as the upregulation ofnegative immune checkpoint molecules on the tumor cells and
tumor-associated immune cells as well as the presence of negative
regulatory cells (T regulatory cells, myeloid-derived suppressor
cells, tumor-associated macrophages etc …). As showed in an
ovarian carcinoma preclinical model, NY-ESO-1-speciﬁc/CD8þ
tumor-inﬁltrating lymphocytes frequently upregulate the negative
immune checkpoint molecules programmed of death-1 (PD-1) and
lymphocyte-activation gene 3 (LAG-3) as immune-escape mecha-
nism [48]. In addition, given the recent approval of checkpoint
inhibitors-based immunotherapy in the metastatic setting of TN
breast cancer [49], we can speculate that some patients might
beneﬁt from the combination of a CT-based peptide vaccine and an
immune checkpoint inhibitor. This hypothesis is currently being
tested in some clinical trials.
5. Conclusions
Our results demonstrated the overexpression of WT1 and NY-
ESO-1 antigen in a group of patients with TN breast cancer for
whom therapeutic options are limited. Exploring the expression of
WT1 and NY-ESO-1 antigens in breast cancer tissue at surgery may
allow to identify patients potentially candidate to adjuvant peptide
vaccines, alone or in combination with other systemic therapies.
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